BioSpace News Archive

Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release fourth quarter 2023 results on Tuesday, February 20, 2024, after the market closes.

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA.

Enzo Biochem, Inc., a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments.

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.

A new study published online and available in the February print edition of the journal Transfusion shows the mixed reality technology for use during blood donation created by Abbott and Blood Centers of America helps ease donors’ feelings of anxiety and boosts the likelihood they will return to give blood again.

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay.

Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company’s newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer’s disease.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development